Evgeniya Kochina

Mrs. Evgeniya Kochina

McGill University, Montréal, Quebec, Canada
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2022 in Viruses
Verified
Journal Article
Open access
PDF file
EKEvgeniya Kochina
Evgeniya Kochina
FUFelix Urusov
Felix Urusov
AKArtem A. Kruglov
Artem A. Kruglov
DGDina Victorovna Glazkova
Dina Victorovna Glazkova
GSGerman Shipulin
German Shipulin
EBElena Bogoslovskaya
Elena Bogoslovskaya
The use of broadly neutralizing antibodies (bNAbs) is a promising approach to HIV-1 treatment. In this work, we evaluate the neutralizing activity of the following HIV-1 bNAbs: VCR07-523, N6, PGDM1400, CAP256-VRC26.25, 10-1074, PGT128, 10E8, and DH511.11P, which are directed to different Env surface epitopes. We used the global panel of HIV-1 pseudoviruses to analyze the bNAbs’ potency and chose the most potent ones. To achieve maximum neutralization breadth and minimum IC50 concentration, the most effective antibodies were tested in double and triple combinations. Among the doubles, the combinations of N6+PGDM1400 and N6+PGT128 with IC50 ≤ 0.3 µg/mL proved to be the most effective. The most effective triple combination was N6+PGDM1400+PGT128. Our data demonstrate that this combination neutralizes pseudoviruses of the global HIV-1 panel with IC50 ≤ 0.11 µg/mL and IC80 ≤ 0.25 µg/mL.